Lilly Claims It’s On Pace To Traverse Its Patent Cliff, Meet Financial Guidance Through 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
As it prepares for the U.S. patent expiration of blockbuster antidepressant Cymbalta later this year, Lilly says it is meeting three strategic priorities it set in 2009, putting it on a path to return to sustainable growth.